Finorify

TWST

Twist Bioscience Corp

$141.38+7.54%

Price

TWST daily closing price
Market cap
$8.82 billion
52W range
$24.16 – $153.10
Volume
2.1M
Sector
Healthcare

Twist Bioscience Corp (TWST) last closed at $141.38, on a daily price path from October 21, 2025 to October 21, 2026. Overview is that price path. Performance is the change in the close over the periods Finorify shows on the stock screen. Financials, cash flow, and margins come from reported quarters. Valuation lists the latest ratios. This snapshot is the Finorify stock screen for TWST, covered for search and blurred for visitors.

Performance

  • 1D+4.51%
  • 5D+0.65%
  • 1M-9.40%
  • 3M+61.33%
  • 6M+135.97%
  • 1Y+355.50%
  • 5Y+35.18%

Financials

TWST revenueQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Over the latest four reported periods ending June 30, 2026, Twist Bioscience Corp reported revenue of $431.8 million.

The prior window totaled $362.3 million, so the latest window is higher than that stretch.

Operating cash flow in the latest window was -$53.1 million.

Free cash flow in the latest window was -$93.1 million.

These amounts are taken from Twist Bioscience Corp's SEC filings and are a snapshot as of June 30, 2026. They are not a live price, and they are not a recommendation to buy or sell. Finorify uses the same filings to draw the charts inside the app.

A few ratios from those statements: Profitability: ROE -7.9% (0 of 100). Cash generation: FCF margin -21.6% (0 of 100). Net margin: -29.6% (0 of 100). Liquidity: Current 2.67× (100 of 100).

Finorify's notes from those filings, written September 7, 2026: Proprietary Silicon-Based DNA Synthesis Platform. Twist's core technological moat is its proprietary semiconductor-based platform that miniaturizes chemical DNA synthesis on silicon chips. By synthesizing thousands of genes in parallel at a fraction of the reagent volume required by traditional 96-well plate methods, Twist achieves superior cost efficiency, higher throughput, and rapid turnaround times that are difficult for legacy competitors to replicate. Broad and Integrated Product Ecosystem. Twist has leveraged its core synthesis engine across multiple high-growth end markets, including synthetic genes, oligo pools for CRISPR/protein engineering, Next-Generation Sequencing (NGS) target enrichment, and biopharma antibody discovery. This product diversification generates recurring commercial relationships across clinical diagnostics, academic research, and pharmaceutical customers. Scalable Manufacturing and Turnaround Advantage. Substantial investments in automated manufacturing infrastructure—including dedicated facilities for high-throughput gene synthesis—enable differentiated product offerings like Express Genes. This scale allows Twist to capture premium pricing for rapid turnaround while progressively expanding gross margins as fixed overhead costs are absorbed over higher unit volumes. Ongoing Operating Losses and Cash Burn. The company has incurred substantial net losses and negative operating cash flows historically. High operating expenses driven by ongoing commercialization, R&D in long-term applications like DNA data storage, and capital investments pose ongoing liquidity and dilution risks if revenue growth fails to outpace expenditure. Technological Disruption and Synthesis Competition. The synthetic biology and genomic tools industries are subject to rapid technological shifts. Twist faces potential disruption from competing synthesis technologies, such as novel enzymatic DNA synthesis platforms or next-generation sequencing advancements that could bypass targeted enrichment methods. Biotechnology Sector Cyclicality and Customer Concentration. A significant portion of Twist's revenue is tied to biotechnology, pharmaceutical, and diagnostic customers who depend on venture funding, capital markets, and corporate R&D budgets. Macroeconomic downturns or pullbacks in early-stage biotech funding directly compress customer demand and order volumes.

Cash Flow

TWST free cash flowQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Margins

TWST operating margin

Valuation

P/S (TTM)
20.43

Insights

Advantage

Proprietary Silicon-Based DNA Synthesis Platform

Twist's core technological moat is its proprietary semiconductor-based platform that miniaturizes chemical DNA synthesis on silicon chips. By synthesizing thousands of genes in parallel at a fraction of the reagent volume required by traditional 96-well plate methods, Twist achieves superior cost efficiency, higher throughput, and rapid turnaround times that are difficult for legacy competitors to replicate.

Advantage

Broad and Integrated Product Ecosystem

Twist has leveraged its core synthesis engine across multiple high-growth end markets, including synthetic genes, oligo pools for CRISPR/protein engineering, Next-Generation Sequencing (NGS) target enrichment, and biopharma antibody discovery. This product diversification generates recurring commercial relationships across clinical diagnostics, academic research, and pharmaceutical customers.

Advantage

Scalable Manufacturing and Turnaround Advantage

Substantial investments in automated manufacturing infrastructure—including dedicated facilities for high-throughput gene synthesis—enable differentiated product offerings like Express Genes. This scale allows Twist to capture premium pricing for rapid turnaround while progressively expanding gross margins as fixed overhead costs are absorbed over higher unit volumes.

Risk

Ongoing Operating Losses and Cash Burn

The company has incurred substantial net losses and negative operating cash flows historically. High operating expenses driven by ongoing commercialization, R&D in long-term applications like DNA data storage, and capital investments pose ongoing liquidity and dilution risks if revenue growth fails to outpace expenditure.

Risk

Technological Disruption and Synthesis Competition

The synthetic biology and genomic tools industries are subject to rapid technological shifts. Twist faces potential disruption from competing synthesis technologies, such as novel enzymatic DNA synthesis platforms or next-generation sequencing advancements that could bypass targeted enrichment methods.

Risk

Biotechnology Sector Cyclicality and Customer Concentration

A significant portion of Twist's revenue is tied to biotechnology, pharmaceutical, and diagnostic customers who depend on venture funding, capital markets, and corporate R&D budgets. Macroeconomic downturns or pullbacks in early-stage biotech funding directly compress customer demand and order volumes.

Read the live analysis in Finorify

Charts, news, and the written notes are in the app. You can open five distinct stocks free. After that, the stock screen is a Finorify Pro feature.

Open TWST in Finorify